Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

CorMedix (CRMD) EBITDA Margin: 2012-2025

Historic EBITDA Margin for CorMedix (CRMD) over the last 12 years, with Sep 2025 value amounting to 0.01%.

  • CorMedix's EBITDA Margin fell 2.00% to 0.01% in Q3 2025 from the same period last year, while for Sep 2025 it was -8.37%, marking a year-over-year increase of 7701.00%. This contributed to the annual value of -41.25% for FY2024, which is 13512366.00% down from last year.
  • CorMedix's EBITDA Margin amounted to 0.01% in Q3 2025, which was up 161.06% from -0.01% recorded in Q2 2025.
  • CorMedix's EBITDA Margin's 5-year high stood at 192,858.54% during Q2 2023, with a 5-year trough of -100,446.94% in Q3 2022.
  • Moreover, its 3-year median value for EBITDA Margin was 0.02% (2025), whereas its average is 38,743.32%.
  • In the last 5 years, CorMedix's EBITDA Margin spiked by 22,868,991bps in 2023 and then tumbled by 19,289,316bps in 2024.
  • Over the past 5 years, CorMedix's EBITDA Margin (Quarterly) stood at -13,829.39% in 2021, then crashed by 1,368,385bps to -27,513.23% in 2022, then skyrocketed by 17,480,561bps to 74,358.67% in 2023, then tumbled by 7,435,864bps to -57.44% in 2024, then declined by 2bps to 0.01% in 2025.
  • Its EBITDA Margin was 0.01% in Q3 2025, compared to -0.01% in Q2 2025 and -0.02% in Q1 2025.